Medifast Inc Stock News

Medifast's collaboration with LifeMD and acquisition of LifeMD shares are expected to boost business growth and free cash flow. The company's holistic approach combining weight loss formulas, coaches, and GLP-1 medication is a significant competitive advantage. Recent investments in marketing and supply chain optimization initiatives, including the Maryland Distribution Center closure, are like...

Medifast, Inc. (NYSE:MED ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson David Larsen - BTIG Operator And welcome to the Medifast Second...

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Revenue of $168.6 million, with revenue per active earning Coach of $4,972 Independent active earning OPTAVIA Coaches of 33,900 Net loss of $8.2 million (n...

The end of the pandemic served as a springboard for the economy, launching us into a new bull market. I can't blame people for being optimistic after seeing the meteoric rise of several big-name stocks.

For the last two years, investors in consumer staples stocks saw every tiny step forward smacked down by two large steps back. Therefore, the 900+-point gain in the Dow Jones Industrial Average (DJIA) the week of July 15 was noteworthy.

Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake.

Novo Nordisk's (NYSE: NVO ) Ozempic diabetes treatment, marketed as a weight loss treatment under the Wegovy brand name, has become the latest mega-blockbuster drug. Yet, while you may be thinking about ways to capitalize on its popularity and the rise of other glucagon-like peptide-1 (GLP-1) weight loss treatments, you should also consider the stocks to sell because of this trend.

Even as the S&P 500 reaches new highs, some investors view small-cap value stocks as the best option for long-term growth. Concerns are growing about the concentration of investments in index-based stocks.